Activa™ Product Family

About Bioretec

Bioretec's mission is to transform orthopedic care by merging biology and technology to create implants that facilitate the body's natural healing process and then safely absorb. Its key achievement is the 2023 FDA approval of RemeOs™, the world's first commercially available absorbable metal orthopedic implant. The company's strategy centers on scaling commercial operations in the United States, advancing its development pipeline, and launching new products to address significant unmet needs in pediatric and adult trauma, sports medicine, and elective procedures. A recent rights issue aims to strengthen its capital base to fund this growth.

Therapeutic Areas